Clinical Trial Detail

NCT ID NCT00697632
Title Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors MethylGene Inc.
Indications

Advanced Solid Tumor

hematologic cancer

Therapies

Glesatinib

Age Groups: adult

Additional content available in CKB BOOST